Welcome to our dedicated page for Evaxion AS news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion AS stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion Biotech (NASDAQ: EVAX) has entered into a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech Holding AB. This partnership aims to develop a novel cytomegalovirus (CMV) vaccine candidate utilizing Evaxion's AI platform, RAVEN, for antigen design. Costs for the collaboration will be split evenly until 2025. A potential future agreement could provide Evaxion with milestone payments and royalties based on CMV asset sublicensing. CMV represents a significant unmet medical need, especially for immunocompromised individuals and congenitally infected infants.
Evaxion Biotech A/S (NASDAQ: EVAX) announced promising interim data from its Phase 1/2a clinical trial for its DNA-based cancer immunotherapy, EVX-02. The treatment, aimed at melanoma, showed a well-tolerated safety profile with only mild adverse events. All patients exhibited robust CD4+ and CD8+ T-cell responses, highlighting the efficacy of their AI-driven technology for personalized cancer treatment. A full report of the trial results is expected in Q2 2023, as the company looks forward to advancing their next-generation DNA technology.
Evaxion Biotech (NASDAQ: EVAX) announced its Q3 2022 financial results, highlighting the enrollment of the first patient in a Phase 2b trial for its cancer immunotherapy EVX-01. The company reported cash and equivalents of $17.9 million, sufficient to support operations into mid-2023. The R&D expenses decreased to $4.1 million compared to $4.4 million in Q3 2021, while general and administrative expenses rose to $2.0 million. Despite a net loss of $5.7 million for the quarter, Evaxion is focused on its oncology assets and pursuing strategic partnerships. Guidance remains optimistic for ongoing projects.
Evaxion Biotech (NASDAQ: EVAX) announced a strategic shift to focus on its leading oncology assets, EVX-01 and EVX-02/03, aiming for clinical proof of concept before potential out-licensing. New CEO Per Norlén emphasized the need for concentration on personalized cancer immunotherapies while preclinical infectious disease programs will seek partnerships. The Phase IIb trial for EVX-01 is underway, with mid-2023 data expected for EVX-02. Promising pre-clinical results for EVX-03 suggest superior efficacy, with plans for regulatory submission following EVX-02 outcomes.
Abalos Therapeutics has appointed Thomas Bogenrieder, MD, PhD, as its new Chief Medical Officer. Dr. Bogenrieder brings over 17 years of international experience in clinical development, particularly in cancer immunotherapies. His expertise will bolster Abalos' efforts in clinical and regulatory strategies for its arenavirus-based product candidates aimed at treating solid tumors. Previously, he served as Chief Medical Officer at Evaxion Biotech and has held senior roles at Boehringer Ingelheim and GlaxoSmithKline. This leadership change is expected to enhance Abalos' innovation in cancer treatment.
Evaxion Biotech A/S (NASDAQ: EVAX) announces the appointment of Per Norlén as its new CEO, effective October 3, 2022. With over 20 years in biotech, Norlén aims to propel Evaxion's capabilities in developing AI-driven immunotherapies for cancer. He expresses confidence in the company’s potential, especially following promising phase 1 trial results in melanoma. Chairman Marianne Soegaard highlights Norlén's leadership as key to advancing the company's innovative clinical and preclinical results. Evaxion is focused on tailored therapies for cancer and other critical diseases.
Evaxion Biotech A/S (NASDAQ: EVAX) announced the enrollment of its first patient in a global Phase 2b clinical trial for EVX-01, a personalized cancer therapy targeting melanoma. This trial, conducted in collaboration with Merck, aims to evaluate the safety and efficacy of EVX-01 alongside KEYTRUDA®. Earlier Phase 1/2a data showed that 67% of patients benefited from the combination treatment, with 22% achieving complete recovery. Interim topline data is anticipated in the second half of 2023, highlighting potential advancements in melanoma treatment.
Evaxion Biotech A/S (NASDAQ: EVAX) has collaborated with UMass Chan Medical School to receive a grant from the U.S. NIH for developing a gonorrhea vaccine candidate. This initiative, part of Evaxion's EVX-B2 project utilizing their AI platform EDEN, aims to address a significant unmet medical need as gonorrhea is a critical antibiotic resistance threat. The vaccine has shown promise in preclinical studies. With the NIH grant, Evaxion intends to advance this innovative vaccine solution to combat gonorrhea infections, which currently lack effective prevention methods.
Evaxion Biotech (NASDAQ: EVAX) reported significant advancements in its immunotherapy programs during Q2 2022, including the expansion into non-small cell lung cancer and production of personalized cancer treatments for melanoma. The company identified gonorrhea as its second bacterial product target. Despite a net loss of $4.8 million and cash reserves of $25.3 million, Evaxion anticipates these funds will support development efforts for the next year. Plans to initiate a Phase 2b trial in partnership with Merck's KEYTRUDA® are also highlighted.
Evaxion Biotech A/S (NASDAQ: EVAX) announces significant executive changes, with Lars Staal Wegner resigning as CEO but staying on as an advisor. Per Norlén, M.D., Ph.D., with over 20 years in clinical drug development, has been appointed as the new CEO. Norlén's experience in oncology and leadership at biopharmaceutical companies is expected to strengthen Evaxion's management as they pursue new partnerships and consolidate future projects. Chair Marianne Soegaard expressed confidence in Norlén's ability to enhance the company's growth and benefit stakeholders.